RxDoctor Payments Data

Adham Malaty, MD

Psychiatry · Santa Barbara, CANPI 1174818587

Payments from drug & device makers

$1,925in general payments, 2019–2025

Across 84 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$466
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$220
  • Vanda Pharmaceuticals Inc.$191
  • Axsome Therapeutics, Inc.$157
  • E.r. Squibb & Sons, L.L.C.$142
  • Otsuka America Pharmaceutical, Inc.$130
  • plus $619 from 9 others

What the payments were for

  • Food & beverage$1,69888%
  • Education$22712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,925 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$124,489
Medicare patients
116
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$29,245
Lurasidone Hcl36$4,068
Ziprasidone Hcl42$2,684
Aripiprazole55$2,580
Mirtazapine136$2,156
Bupropion Hcl SrBupropion Hcl83$2,141
Fluoxetine Hcl115$1,399
Divalproex Sodium ErDivalproex Sodium27$1,232
Venlafaxine Hcl ErVenlafaxine Hcl45$1,197
Quetiapine Fumarate63$1,169
Escitalopram Oxalate60$857
Lamotrigine52$840
Sertraline Hcl95$838
Bupropion XlBupropion Hcl43$800
Olanzapine17$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$91$29,24513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →